Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report

Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report

A case study using mammalian target of rapamycin complex 1 in recurrent ovarian clear cell carcinoma (CCC) was recently conducted. We report our experience with a patient suffering from recurrent ovarian CCC who achieved long-term disease control with everolimus administration. The patient was a 53-...

Full description

Bibliographic Details
Main Authors: Takatori, Eriko, Shoji, Tadahiro, Miura, Yuki, Takada, Anna, Takeuchi, Satoshi, Sugiyama, Toru
Format: Online
Language:English
Published: Dove Medical Press 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913549/
id pubmed-3913549
recordtype oai_dc
spelling pubmed-39135492014-02-07 Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report Takatori, Eriko Shoji, Tadahiro Miura, Yuki Takada, Anna Takeuchi, Satoshi Sugiyama, Toru Case Report A case study using mammalian target of rapamycin complex 1 in recurrent ovarian clear cell carcinoma (CCC) was recently conducted. We report our experience with a patient suffering from recurrent ovarian CCC who achieved long-term disease control with everolimus administration. The patient was a 53-year-old woman who was diagnosed with recurrent ovarian CCC with dissemination throughout the abdominal cavity. Previously, she had received three chemotherapy regimens, but the disease was progressive and she showed no response to treatment. Therefore, oral everolimus administration (everolimus 10 mg/day on days 1–28, a 28-day period comprised one cycle) was started. She was administered six cycles. The antitumor response was stable disease, and grade 3 anemia was observed. Chemotherapy was then switched to gemcitabine/docetaxel therapy. In the middle of the second cycle, a rapid increase in ascitic fluid and CA125 elevation were observed. Thereafter, the patient received best supportive care and died of the disease. Everolimus may inhibit malignant progression of ovarian CCC. Dove Medical Press 2014-01-29 /pmc/articles/PMC3913549/ /pubmed/24511239 http://dx.doi.org/10.2147/OTT.S54745 Text en © 2014 Takatori et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Takatori, Eriko
Shoji, Tadahiro
Miura, Yuki
Takada, Anna
Takeuchi, Satoshi
Sugiyama, Toru
spellingShingle Takatori, Eriko
Shoji, Tadahiro
Miura, Yuki
Takada, Anna
Takeuchi, Satoshi
Sugiyama, Toru
Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report
author_facet Takatori, Eriko
Shoji, Tadahiro
Miura, Yuki
Takada, Anna
Takeuchi, Satoshi
Sugiyama, Toru
author_sort Takatori, Eriko
title Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report
title_short Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report
title_full Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report
title_fullStr Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report
title_full_unstemmed Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report
title_sort effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report
description A case study using mammalian target of rapamycin complex 1 in recurrent ovarian clear cell carcinoma (CCC) was recently conducted. We report our experience with a patient suffering from recurrent ovarian CCC who achieved long-term disease control with everolimus administration. The patient was a 53-year-old woman who was diagnosed with recurrent ovarian CCC with dissemination throughout the abdominal cavity. Previously, she had received three chemotherapy regimens, but the disease was progressive and she showed no response to treatment. Therefore, oral everolimus administration (everolimus 10 mg/day on days 1–28, a 28-day period comprised one cycle) was started. She was administered six cycles. The antitumor response was stable disease, and grade 3 anemia was observed. Chemotherapy was then switched to gemcitabine/docetaxel therapy. In the middle of the second cycle, a rapid increase in ascitic fluid and CA125 elevation were observed. Thereafter, the patient received best supportive care and died of the disease. Everolimus may inhibit malignant progression of ovarian CCC.
publisher Dove Medical Press
publishDate 2014
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913549/
_version_ 1612054683755479040

Similar Items